Abstract 2105P
Background
Abemaciclib-induced diarrhea represents a major concern in clinical practice, as it can severely affect patients' quality of life and cause treatment discontinuation and dose modifications. Since growing evidence emphasize the role of microbiota in abnormal bowel clinical manifestations, a new class of natural molecules, called postbiotics, offers a potential option for managing abemaciclib-induced diarrhea.
Methods
We conducted a prospective, observational, single-arm study to evaluate the effect of the postbiotic food supplement “PostbiotiX-RestoreTM” on abemaciclib-induced diarrhea. We enrolled 36 hormone receptor-positive HER2-negative breast cancer (BC) patients at IRCCS Humanitas Research Hospital. The postbiotic was administered once daily from day -7 to the end of the first cycle of abemaciclib. From day-7 and until the end of the second cycle of abemaciclib, patients reported a daily questionnaire on bowel movements, concomitant medications, diet, and treatment discontinuation. Diarrhea was defined according to version 4.0 of the National Cancer Institute’s Common Terminology Criteria for Adverse Events. Incidence of diarrhea of any grade, its median duration and median time to diarrhea onset were assessed.
Results
An overall regularization of bowel movements in the first week of treatment with PostbioticX-RestoreTM alone was reported. Diarrhea events occurred in all patients, but predominantly G1 (87.1%) and G2 (12.3%), with a very low percentage of G3 (0.6%; all occurring during the second cycle, off postbiotic) and no G4 events. The median time to diarrhea onset was 4 days (IQR 1-41) with a median duration of G1, G2, and G3 events of 4 (IQR 1-17), 1 (IQR 1-5), and 1 (IQR 1-1) days, respectively. There was only one case of dose reduction (during the second cycle, off postbiotic) and no case of treatment withdrawal due to diarrhea.
Conclusions
Our results suggest a promising effect of PostbioticX-RestoreTM in the management of abemaciclib-induced diarrhea. Compared to pivotal trials on abemaciclib in BC patients, we observed a reduced severity and shorter duration of diarrhea.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2078P - Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: Results of a survey of healthcare providers in Japan
Presenter: Florian Scotté
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06